Gaurav Aggarwal
Director · Unicycive Therapeutics, Inc.
Individual
- 2024
- Aug 25, 2025
- 3
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Gaurav Aggarwal's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Michael Benkowitz - $135.23M in UTHR purchases and sales in the last 12 months
- Andrew T. Kaplan - $134.38M in KLRA purchases and sales in the last 12 months
- BAIN CAPITAL INVESTORS LLC - $134.38M in KLRA purchases and sales in the last 12 months
- Fairmount Funds Management LLC - $133.53M in APGE purchases and sales in the last 12 months
- Stephen M. Bloch - $125.05M in LQDA purchases and sales in the last 12 months
- Jason P. Rhodes - $124.92M in DYN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Gaurav Aggarwal?
Gaurav Aggarwal is a corporate insider, tracked as Director of Unicycive Therapeutics, Inc. (UNCY). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Gaurav Aggarwal last file a Form 4?
The most recent primary Form 4 on record is dated 25 August 2025, one of 3 filings going back to 2024.
